Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
MedPage Today on MSN5d
Better Response, Survival in Head and Neck Cancer With Dual Pre-Op ImmunotherapyTwo neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...
CS2009's mechanism of action ... CS2009 showed stronger anti-tumour effects than both PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies; and in toxicology studies, CS2009 exhibited a safety margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback